Cancer cachexia update in head and neck cancer: Definitions and diagnostic features

Head and Neck

Volumn 37, Issue 4, 2015, Pages 594-604

  Couch, Marion E ^a   Dittus, Kim ^a   Toth, Michael J ^a   Willis, Monte S ^b   Guttridge, Denis C ^c   George, Jonathan R ^d   Barnes, Christie A ^a   Gourin, Christine G ^e   Der Torossian, Hirak ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

cancer cachexia and anorexia; cardiac dysfunction; head and neck cancer; meta analysis; weight loss

Indexed keywords

BIOLOGICAL MARKER;

CACHEXIA; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CINAHL; COCHRANE LIBRARY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE MARKER; HEAD AND NECK CANCER; HEART FAILURE; HUMAN; MEDLINE; MORBIDITY; OBESITY; PARANEOPLASTIC SYNDROME; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SEX DIFFERENCE; WEIGHT REDUCTION; CANCER STAGING; COMPLICATION; HEAD AND NECK TUMOR; META ANALYSIS; PATHOLOGY; PATHOPHYSIOLOGY; PREVALENCE; PROGNOSIS;

CACHEXIA; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASM STAGING; PREVALENCE; PROGNOSIS; QUALITY OF LIFE; WEIGHT LOSS;

EID: 84925688977     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.23599     Document Type: Review

References (148)

1. Der-Torossian H, Asher SA, Winnike JH, et al. Cancer cachexia's metabolic signature in a murine model confirms a distinct entity. Metabolomics 2012; 9: 730-739.
2. Morley JE, Thomas DR, Wilson MM,. Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr 2006; 83: 735-743.
3. Stewart GD, Skipworth RJ, Fearon K,. The anorexia-cachexia syndrome. In:, Walsh D, editor. Palliative Medicine. Philadelphia, PA: Saunders/Elsevier; 2009. pp 587-595.
4. Snyderman CH,. Nutrition and head and neck cancer. Curr Oncol Rep 2003; 5: 158-163.
5. Laviano A, Meguid MM,. Nutritional issues in cancer management. Nutrition 1996; 12: 358-371.
6. Ramos Chaves M, Boléo-Tomé C, Monteiro-Grillo I, Camilo M, Ravasco P,. The diversity of nutritional status in cancer: new insights. Oncologist 2010; 15: 523-530.
7. Lucia S, Esposito M, Rossi Fanelli F, Muscaritoli M,. Cancer cachexia: from molecular mechanisms to patient's care. Crit Rev Oncog 2012; 17: 315-321.
8. Stewart GD, Skipworth RJ, Fearon KC,. Cancer cachexia and fatigue. Clin Med 2006; 6: 140-143.
9. Der-Torossian H, Gourin CG, Couch ME,. Translational implications of novel findings in cancer cachexia: the use of metabolomics and the potential of cardiac malfunction. Curr Opin Support Palliat Care 2012; 6: 446-450.
10. Neyeloff JL, Fuchs SC, Moreira LB,. Meta-analyses and Forest plots using a Microsoft Excel spreadsheet: step-by-step guide focusing on descriptive data analysis. BMC Res Notes 2012; 5: 52.
11. Evans WJ, Morley JE, Argilés J, et al. Cachexia: a new definition. Clin Nutr 2008; 27: 793-799.
12. Jager-Wittenaar H, Dijkstra PU, Vissink A, van der Laan BF, van Oort RP, Roodenburg JL,. Critical weight loss in head and neck cancer-prevalence and risk factors at diagnosis: an explorative study. Support Care Cancer 2007; 15: 1045-1050.
13. Wiel E, Costecalde ME, Séguy D, et al. [Perioperative evolution of the nutritional status in head and neck surgical patients. Prospective and descriptive case series]. Ann Fr Anesth Reanim 2005; 24: 600-606 [Article in French].
14. Silver HJ, Dietrich MS, Murphy BA,. Changes in body mass, energy balance, physical function, and inflammatory state in patients with locally advanced head and neck cancer treated with concurrent chemoradiation after low-dose induction chemotherapy. Head Neck 2007; 29: 893-900.
15. Andreoli A, De Lorenzo A, Cadeddu F, Iacopino L, Grande M,. New trends in nutritional status assessment of cancer patients. Eur Rev Med Pharmacol Sci 2011; 15: 469-480.
16. Couch M, Lai V, Cannon T, et al. Cancer cachexia syndrome in head and neck cancer patients: part I. Diagnosis, impact on quality of life and survival, and treatment. Head Neck 2007; 29: 401-411.
17. Mick R, Vokes EE, Weichselbaum RR, Panje WR,. Prognostic factors in advanced head and neck cancer patients undergoing multimodality therapy. Otolaryngol Head Neck Surg 1991; 105: 62-73.
18. Petruson KM, Silander EM, Hammerlid EB,. Quality of life as predictor of weight loss in patients with head and neck cancer. Head Neck 2005; 27: 302-310.
19. van den Berg MG, Rasmussen-Conrad EL, Wei KH, Lintz-Luidens H, Kaanders JH, Merkx MA,. Comparison of the effect of individual dietary counselling and of standard nutritional care on weight loss in patients with head and neck cancer undergoing radiotherapy. Br J Nutr 2010; 104: 872-877.
20. Brookes GB,. Nutritional status - a prognostic indicator in head and neck cancer. Otolaryngol Head Neck Surg 1985; 93: 69-74.
21. Wood RM, Lander VL, Mosby EL, Hiatt WR,. Nutrition and the head and neck cancer patient. Oral Surg Oral Med Oral Pathol 1989; 68: 391-395.
22. Matthews TW, Lampe HB, Dragosz K,. Nutritional status in head and neck cancer patients. J Otolaryngol 1995; 24: 87-91.
23. Büntzel J, Küttner K,. [Value of megestrol acetate in treatment of cachexia in head-neck tumors]. Laryngorhinootologie 1995; 74: 504-507 [Article in German].
24. van Bokhorst-de van der Schueren MA, van Leeuwen PA, Sauerwein HP, Kuik DJ, Snow GB, Quak JJ,. Assessment of malnutrition parameters in head and neck cancer and their relation to postoperative complications. Head Neck 1997; 19: 419-425.
25. Mascarin M, Franchin G, Minatel E, et al. The effect of granulocyte colony-stimulating factor on oral mucositis in head and neck cancer patients treated with hyperfractionated radiotherapy. Oral Oncol 1999; 35: 203-208.
26. Lees J,. Incidence of weight loss in head and neck cancer patients on commencing radiotherapy treatment at a regional oncology centre. Eur J Cancer Care (Engl) 1999; 8: 133-136.
27. Mantovani G, Proto E, Massa E, et al. Induction chemotherapy followed by concomitant chemoradiation therapy in advanced head and neck cancer: a phase II study for organ-sparing purposes evaluating feasibility, effectiveness and toxicity. Int J Oncol 2002; 20: 419-427.
28. Ravasco P, Monteiro-Grillo I, Vidal PM, Camilo ME,. Nutritional deterioration in cancer: the role of disease and diet. Clin Oncol (R Coll Radiol) 2003; 15: 443-450.
29. Martín Villares C, San Román Carbajo J, Fernández Pello ME, Tapia Risueño M, Domínguez Calvo J,. [Nutritional status in head and neck cancer patients: the impact on the prognoses]. Nutr Hosp 2003; 18: 91-94 [Article in Spanish].
30. van den Broek GB, Rasch CR, Pameijer FA, et al. Pretreatment probability model for predicting outcome after intraarterial chemoradiation for advanced head and neck carcinoma. Cancer 2004; 101: 1809-1817.
31. Bahl M, Siu LL, Pond GR, et al. Tolerability of the Intergroup 0099 (INT 0099) regimen in locally advanced nasopharyngeal cancer with a focus on patients' nutritional status. Int J Radiat Oncol Biol Phys 2004; 60: 1127-1136.
32. Maio R, Berto JC, Côrrea CR, Campana AO, Paiva SAR,. [Nutritional status and inflammatory markers of preoperative oral cavity and oropharynx cancer patients]. Rev Bras Canc. 2009; 55: 345-353 [Article in Portuguese].
33. Pressoir M, Desné S, Berchery D, et al. Prevalence, risk factors and clinical implications of malnutrition in French Comprehensive Cancer Centres. Br J Cancer 2010; 102: 966-971.
34. Koiwai K, Shikama N, Sasaki S, Shinoda A, Kadoya M,. Validation of the Total Dysphagia Risk Score (TDRS) as a predictive measure for acute swallowing dysfunction induced by chemoradiotherapy for head and neck cancers. Radiother Oncol 2010; 97: 132-135.
35. Jager-Wittenaar H, Dijkstra PU, Vissink A, et al. Changes in nutritional status and dietary intake during and after head and neck cancer treatment. Head Neck 2011; 33: 863-870.
36. Valentini V, Marazzi F, Bossola M, et al. Nutritional counselling and oral nutritional supplements in head and neck cancer patients undergoing chemoradiotherapy. J Hum Nutr Diet 2012; 25: 201-208.
37. Bhayani MK, Hutcheson KA, Barringer DA, et al. Gastrostomy tube placement in patients with oropharyngeal carcinoma treated with radiotherapy or chemoradiotherapy: factors affecting placement and dependence. Head Neck 2013; 35: 1634-1640.
38. van den Berg MG, Rasmussen-Conrad EL, Gwasara GM, Krabbe PF, Naber AH, Merkx MA,. A prospective study on weight loss and energy intake in patients with head and neck cancer, during diagnosis, treatment and revalidation. Clin Nutr 2006; 25: 765-772.
39. Nourissat A, Bairati I, Samson E, et al. Predictors of weight loss during radiotherapy in patients with stage I or II head and neck cancer. Cancer 2010; 116: 2275-2283.
40. Bruzgielewicz A, Hamera M, Osuch-Wõjcikiewicz E,. [Nutritional status of patients with cancer of larynx and hypopharyx]. Otolaryngol Pol 2009; 63: 141-146 [Article in Polish].
41. Collins MM, Wight RG, Partridge G,. Nutritional consequences of radiotherapy in early laryngeal carcinoma. Ann R Coll Surg Engl 1999; 81: 376-381.
42. Goodwin WJ Jr, Byers PM,. Nutritional management of the head and neck cancer patient. Med Clin North Am 1993; 77: 597-610.
43. Cady J,. Nutritional support during radiotherapy for head and neck cancer: the role of prophylactic feeding tube placement. Clin J Oncol Nurs 2007; 11: 875-880.
44. Grobbelaar EJ, Owen S, Torrance AD, Wilson JA,. Nutritional challenges in head and neck cancer. Clin Otolaryngol Allied Sci 2004; 29: 307-313.
45. Hammerlid E, Wirblad B, Sandin C, et al. Malnutrition and food intake in relation to quality of life in head and neck cancer patients. Head Neck 1998; 20: 540-548.
46. Ravasco P, Monteiro-Grillo I, Vidal PM, Camilo ME,. Cancer: disease and nutrition are key determinants of patients' quality of life. Support Care Cancer 2004; 12: 246-252.
47. Ravasco P, Monteiro-Grillo I, Camilo ME,. Does nutrition influence quality of life in cancer patients undergoing radiotherapy? Radiother Oncol 2003; 67: 213-220.
48. Poterucha T, Burnette B, Jatoi A,. A decline in weight and attrition of muscle in colorectal cancer patients receiving chemotherapy with bevacizumab. Med Oncol 2012; 29: 1005-1009.
49. Sproat K, Russell C,. Malnutrition (a hidden cost in health care). Columbus, Ohio: Ross Products Division, Abbott Laboratories; 1994.
50. Zogbaum AT, Fitz P, Duffy VB,. Tube feeding may improve adherence to radiation treatment schedule in head and neck cancer: an outcomes study. Top Clin Nutr 2004; 19: 95-106.
51. Larsson M, Hedelin B, Johansson I, Athlin E,. Eating problems and weight loss for patients with head and neck cancer: a chart review from diagnosis until one year after treatment. Cancer Nurs 2005; 28: 425-435.
52. von Meyenfeldt M,. Cancer-associated malnutrition: an introduction. Eur J Oncol Nurs 2005; 9 Suppl 2: S35-S38.
53. Kim HL, Han KR, Zisman A, Figlin RA, Belldegrun AS,. Cachexia-like symptoms predict a worse prognosis in localized t1 renal cell carcinoma. J Urol 2004; 171: 1810-1813.
54. Andreyev HJ, Norman AR, Oates J, Cunningham D,. Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer 1998; 34: 503-509.
55. Nayel H, el-Ghoneimy E, el-Haddad S,. Impact of nutritional supplementation on treatment delay and morbidity in patients with head and neck tumors treated with irradiation. Nutrition 1992; 8: 13-18.
56. Galvan O, Sprinzl GM, Widner B, Hackl JM, Gunkel AR, Thumfart WF,. [Value of a nutrition score in patients with advanced carcinomas in the area of the head and neck]. HNO 2000; 48: 928-936 [Article in German].
57. Lorenz KJ, Müller V, Maier H,. [Enteral feeding therapy in patients with head and neck neoplasms]. HNO 1997; 45: 939-950 [Article in German].
58. Inagaki J, Rodriguez V, Bodey GP,. Proceedings: causes of death in cancer patients. Cancer 1974; 33: 568-573.
59. Shao JZ, Ye MZ, Gu JF,. Parenteral nutrition. Shangai: Shangai Scientific and Technology Publishing House; 1984.
60. Sesterhenn AM, Szalay A, Zimmermann AP, Werner JA, Barth PJ, Wiegand S,. [Significance of autopsy in patients with head and neck cancer]. Laryngorhinootologie 2012; 91: 375-380.
61. Prakash G, Bakhshi S, Raina V, et al. Characteristics and pattern of mortality in cancer patients at a tertiary care oncology center: report of 259 cases. Asian Pac J Cancer Prev 2010; 11: 1755-1759.
62. Tisdale MJ,. Cachexia in cancer patients. Nat Rev Cancer 2002; 2: 862-871.
63. Prado CM, Lieffers JR, McCargar LJ, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol 2008; 9: 629-635.
64. Evans WJ,. Skeletal muscle loss: cachexia, sarcopenia, and inactivity. Am J Clin Nutr 2010; 91: 1123S-1127S.
65. Tisdale MJ,. Cancer cachexia: metabolic alterations and clinical manifestations. Nutrition 1997; 13: 1-7.
66. Pai PC, Chuang CC, Tseng CK, et al. Impact of pretreatment body mass index on patients with head-and-neck cancer treated with radiation. Int J Radiat Oncol Biol Phys 2012; 83: e93-e100.
67. Yueh B, Feinstein AR, Weaver EM, Sasaki CT, Concato J,. Prognostic staging system for recurrent, persistent, and second primary cancers of the oral cavity and oropharynx. Arch Otolaryngol Head Neck Surg 1998; 124: 975-981.
68. Datema FR, Ferrier MB, Baatenburg de Jong RJ,. Impact of severe malnutrition on short-term mortality and overall survival in head and neck cancer. Oral Oncol 2011; 47: 910-914.
69. Costa G,. Cachexia, the metabolic component of neoplastic diseases. Cancer Res 1977; 37 (7 Pt 2): 2327-2335.
70. Cannon TY, Guttridge D, Dahlman J, et al. The effect of altered Toll-like receptor 4 signaling on cancer cachexia. Arch Otolaryngol Head Neck Surg 2007; 133: 1263-1269.
71. Vahle AK, Kerem A, Oztürk E, Bankfalvi A, Lang S, Brandau S,. Optimization of an orthotopic murine model of head and neck squamous cell carcinoma in fully immunocompetent mice - role of toll-like-receptor 4 expressed on host cells. Cancer Lett 2012; 317: 199-206.
72. Tan BH, Ross JA, Kaasa S, Skorpen F, Fearon KC,; European Palliative Care Research Collaborative. Identification of possible genetic polymorphisms involved in cancer cachexia: a systematic review. J Genet 2011; 90: 165-177.
73. Nitenberg G, Raynard B,. Nutritional support of the cancer patient: issues and dilemmas. Crit Rev Oncol Hematol 2000; 34: 137-168.
74. O'Neill JP, Shaha AR,. Nutrition management of patients with malignancies of the head and neck. Surg Clin North Am 2011; 91: 631-639.
75. van Wayenburg CA, Rasmussen-Conrad EL, van den Berg MG, et al. Weight loss in head and neck cancer patients little noticed in general practice. J Prim Health Care 2010; 2: 16-21.
76. De Luis DA, Izaola O, Aller R,. Nutritional status in head and neck cancer patients. Eur Rev Med Pharmacol Sci 2007; 11: 239-243.
77. Dillon EL, Basra G, Horstman AM, et al. Cancer cachexia and anabolic interventions: a case report. J Cachexia Sarcopenia Muscle 2012; 3: 253-263.
78. Isenring EA, Capra S, Bauer JD,. Nutrition intervention is beneficial in oncology outpatients receiving radiotherapy to the gastrointestinal or head and neck area. Br J Cancer 2004; 91: 447-452.
79. Platek ME, Popp JV, Possinger CS, Denysschen CA, Horvath P, Brown JK,. Comparison of the prevalence of malnutrition diagnosis in head and neck, gastrointestinal, and lung cancer patients by 3 classification methods. Cancer Nurs 2011; 34: 410-416.
80. Kubrak C, Olson K, Jha N, et al. Nutrition impact symptoms: key determinants of reduced dietary intake, weight loss, and reduced functional capacity of patients with head and neck cancer before treatment. Head Neck 2010; 32: 290-300.
81. Kruizenga HM, Wierdsma NJ, van Bokhorst MA, et al. Screening of nutritional status in The Netherlands. Clin Nutr 2003; 22: 147-152.
82. Ferguson M,. Patient-generated subjective global assessment. In:, McCallum PD, Polisena CG, editors. The Clinical Guide to Oncology Nutrition. Chicago, Illinois: The American Dietetic Association; 2000.
83. Perry GS, Byers TE, Mokdad AH, Serdula MK, Williamson DF,. The validity of self-reports of past body weights by U.S. adults. Epidemiology 1995; 6: 61-66.
84. Stunkard AJ, Albaum JM,. The accuracy of self-reported weights. Am J Clin Nutr 1981; 34: 1593-1599.
85. Argilés JM, Lõpez-Soriano FJ, Toledo M, Betancourt A, Serpe R, Busquets S,. The cachexia score (CASCO): a new tool for staging cachectic cancer patients. J Cachexia Sarcopenia Muscle 2011; 2: 87-93.
86. Sarhill N, Mahmoud FA, Christie R, Tahir A,. Assessment of nutritional status and fluid deficits in advanced cancer. Am J Hosp Palliat Care 2003; 20: 465-473.
87. Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011; 12: 489-495.
88. Baracos V,. Measurement of lean body mass using CT scans. The 110th Abbott Nutrition Research Conference. Columbus, Ohio: Abbott Nutrition Health Institute; 2009. pp 1-26.
89. Mourtzakis M, Prado CM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE,. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab 2008; 33: 997-1006.
90. Ross R, Janssen I,. Computed tomography and magnetic resonance imaging. In:, Heymsfield S, Lohman T, Wang Z, Going S, editors. Human body composition. Champaign, Illinois: Human Kinetics; 2005. p. 523.
91. Shen W, Punyanitya M, Wang Z, et al. Visceral adipose tissue: relations between single-slice areas and total volume. Am J Clin Nutr 2004; 80: 271-278.
92. Shen W, Punyanitya M, Wang Z, et al. Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol (1985) 2004; 97: 2333-2338.
93. McRackan TR, Watkins JM, Herrin AE, et al. Effect of body mass index on chemoradiation outcomes in head and neck cancer. Laryngoscope 2008; 118: 1180-1185.
94. Der-Torossian H, Asher S, Wysong A, et al. Cancer cachexia's metabolic fingerprint in a murine model confirms a distinct entity. Meeting abstracts from the 8th International Conference on Head and Neck Cancer, July 22-24, 2012; abstract #P163.
95. O'Connell TM, Ardeshirpour F, Asher SA, et al. Metabolomic analysis of cancer cachexia reveals distinct lipid and glucose alterations. Metabolomics 2008; 4: 216-225.
96. Fearon KC, Glass DJ, Guttridge DC,. Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab 2012; 16: 153-166.
97. Tjepkema M,. Measured obesity: adult obesity in Canada: measured height and weight. Available at: http://www.aboutmen.ca/application/www.aboutmen.ca/asset/upload/tiny-mce/page/link/Adult-Obesity-in-Canada.pdf. Accessed July 2, 2013.
98. Flegal KM, Carroll MD, Ogden CL, Curtin LR,. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010; 303: 235-241.
99. Martin L, Birdsell L, Macdonald N, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol 2013; 31: 1539-1547.
100. Jager-Wittenaar H, Dijkstra PU, Vissink A, van Oort RP, van der Laan BF, Roodenburg JL,. Malnutrition in patients treated for oral or oropharyngeal cancer - prevalence and relationship with oral symptoms: an explorative study. Support Care Cancer 2011; 19: 1675-1683.
101. Sukkar SG,; The ONCONUT Project Group. The impact of clinical nutrition on cancer therapy: a frequently underestimated perspective. A complementary approach to cancer patients. Med J Nutrition Metab 2012; 5: 75-79.
102. Baumgartner RN,. Body composition in healthy aging. Ann N Y Acad Sci 2000; 904: 437-448.
103. Sarhill N, Mahmoud F, Walsh D, et al. Evaluation of nutritional status in advanced metastatic cancer. Support Care Cancer 2003; 11: 652-659.
104. Büntzel J, Krauß T, Büntzel H, et al. Nutritional parameters for patients with head and neck cancer. Anticancer Res 2012; 32: 2119-2123.
105. Carney DE, Meguid MM,. Current concepts in nutritional assessment. Arch Surg 2002; 137: 42-45.
106. Thoresen L, Frykholm G, Lydersen S, et al. Nutritional status, cachexia and survival in patients with advanced colorectal carcinoma. Different assessment criteria for nutritional status provide unequal results. Clin Nutr 2013; 32: 65-72.
107. Loh KW, Vriens MR, Gerritsen A, et al. Unintentional weight loss is the most important indicator of malnutrition among surgical cancer patients. Neth J Med 2012; 70: 365-369.
108. Edington J, Winter PD, Coles SJ, Gale CR, Martyn CN,. Outcomes of undernutrition in patients in the community with cancer or cardiovascular disease. Proc Nutr Soc 1999; 58: 655-661.
109. Stephens NA, Gray C, MacDonald AJ, et al. Sexual dimorphism modulates the impact of cancer cachexia on lower limb muscle mass and function. Clin Nutr 2012; 31: 499-505.
110. Baracos VE, Reiman T, Mourtzakis M, Gioulbasanis I, Antoun S,. Body composition in patients with non-small cell lung cancer: a contemporary view of cancer cachexia with the use of computed tomography image analysis. Am J Clin Nutr 2010; 91: 1133S-1137S.
111. Brown JK,. Gender, age, usual weight, and tobacco use as predictors of weight loss in patients with lung cancer. Oncol Nurs Forum 1993; 20: 466-472.
112. Cosper PF, Leinwand LA,. Cancer causes cardiac atrophy and autophagy in a sexually dimorphic manner. Cancer Res 2011; 71: 1710-1720.
113. Häkkinen K,. Neuromuscular fatigue and recovery in male and female athletes during heavy resistance exercise. Int J Sports Med 1993; 14: 53-59.
114. Varma M, Chai JK, Meguid MM, Yang ZJ,. Gender differences in tumor-induced anorectic feeding pattern in Fischer-344 rats. Physiol Behav 2001; 74: 29-35.
115. Palomares MR, Lillington L, Shekar K, Grosvenor M, Sayre J, Chlebowski RT,. Clinical outcome, gender, and weight loss in non-small cell lung cancer. Proc Am Soc Clin Oncol 1996; 15: 1407.
116. Grosvenor M, Bulcavage L, Chlebowski RT,. Symptoms potentially influencing weight loss in a cancer population. Correlations with primary site, nutritional status, and chemotherapy administration. Cancer 1989; 63: 330-334.
117. Shores MM, Matsumoto AM, Sloan KL, Kivlahan DR,. Low serum testosterone and mortality in male veterans. Arch Intern Med 2006; 166: 1660-1665.
118. Shores MM, Sloan KL, Matsumoto AM, Moceri VM, Felker B, Kivlahan DR,. Increased incidence of diagnosed depressive illness in hypogonadal older men. Arch Gen Psychiatry 2004; 61: 162-167.
119. Remenár E,. [Cytogenetic and hormonal changes in head and neck squamous cell cancer patients: potential biomarkers for functional approaches in surgical oncology]. Magy Onkol 2009; 53: 157-164 [Article in Hungarian].
120. Remenár E, Számel I, Budai B, et al. [Prognostic significance of sex steroid and hypophyseal hormones in head and neck squamous cell carcinoma]. Magy Onkol 2003; 47: 155-159 [Article in Hungarian].
121. Kleemann D, Kunkel S,. [Serum dihydrotestosterone versus total testosterone values of patients with laryngeal carcinomas and chronic laryngitis]. Laryngorhinootologie 1996; 75: 351-355 [Article in German].
122. Chlebowski RT, Heber D,. Hypogonadism in male patients with metastatic cancer prior to chemotherapy. Cancer Res 1982; 42: 2495-2498.
123. Greenfield DM, Walters SJ, Coleman RE, et al. Prevalence and consequences of androgen deficiency in young male cancer survivors in a controlled cross-sectional study. J Clin Endocrinol Metab 2007; 92: 3476-3482.
124. Remenár E, Számel I, Budai B, et al. Increase of hypophyseal hormone levels in male head and neck cancer patients. Pathol Oncol Res 2007; 13: 341-344.
125. Garcia JM, Li H, Mann D, et al. Hypogonadism in male patients with cancer. Cancer 2006; 106: 2583-2591.
126. Simons JP, Schols AM, Buurman WA, Wouters EF,. Weight loss and low body cell mass in males with lung cancer: relationship with systemic inflammation, acute-phase response, resting energy expenditure, and catabolic and anabolic hormones. Clin Sci (Lond) 1999; 97: 215-223.
127. Horstman AM, Dillon EL, Urban RJ, Sheffield-Moore M,. The role of androgens and estrogens on healthy aging and longevity. J Gerontol A Biol Sci Med Sci 2012; 67: 1140-1152.
128. Vigano A, Piccioni M, Trutschnigg B, Hornby L, Chaudhury P, Kilgour R,. Male hypogonadism associated with advanced cancer: a systematic review. Lancet Oncol 2010; 11: 679-684.
129. Wilson JD, Griffin JE,. The use and misuse of androgens. Metabolism 1980; 29: 1278-1295.
130. Roubenoff R, Hughes VA,. Sarcopenia: current concepts. J Gerontol A Biol Sci Med Sci 2000; 55: M716-M724.
131. Del Fabbro E, Hui D, Nooruddin ZI, et al. Associations among hypogonadism, C-reactive protein, symptom burden, and survival in male cancer patients with cachexia: a preliminary report. J Pain Symptom Manage 2010; 39: 1016-1024.
132. Yialamas MA, Dwyer AA, Hanley E, Lee H, Pitteloud N, Hayes FJ,. Acute sex steroid withdrawal reduces insulin sensitivity in healthy men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 2007; 92: 4254-4259.
133. Strasser F, Palmer JL, Schover LR, et al. The impact of hypogonadism and autonomic dysfunction on fatigue, emotional function, and sexual desire in male patients with advanced cancer: a pilot study. Cancer 2006; 107: 2949-2957.
134. Chlebowski RT, Herrold J, Ali I, et al. Influence of nandrolone decanoate on weight loss in advanced non-small cell lung cancer. Cancer 1986; 58: 183-186.
135. Zhou X, Wang JL, Lu J, et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 2010; 142: 531-543.
136. Hellerstein HK, Santiago-Stevenson D,. Atrophy of the heart; a correlative study of 85 proved cases. Circulation 1950; 1: 93-126.
137. Wysong A, Couch M, Shadfar S, et al. NF- K B inhibition protects against tumor-induced cardiac atrophy in vivo. Am J Pathol 2011; 178: 1059-1068.
138. Shadfar S, Couch M, McKinney K, et al. Oral resveratrol therapy inhibits cancer-induced skeletal muscle and cardiac atrophy in vivo. Nutr Cancer 2011; 63: 749-762.
139. Xu H, Crawford D, Hutchinson KR, et al. Myocardial dysfunction in an animal model of cancer cachexia. Life Sci 2011; 88: 406-410.
140. Springer J, Hartmann A, Palus S, Grzesiak A, Aaschia E, Anker S,. Development of Severe Progressive Heart Failure in Experimental Cancer Cachexia. The 13th Annual Scientific Meeting of Heart Failure Society of America. Boston, MA; September 13-16, 2009.
141. Springer J, Tschirner A, Palus S, et al. Severe progressive heart failure in experimental cancer cachexia only transiently elevates B-type natriuretic peptide (BNP). Abstracts of the 5th Cachexia Conference, Barcelona, Spain, December 5-8, 2009.
142. Tian M, Nishijima Y, Asp ML, Stout MB, Reiser PJ, Belury MA,. Cardiac alterations in cancer-induced cachexia in mice. Int J Oncol 2010; 37: 347-353.
143. El-Menyar AA,. Cytokines and myocardial dysfunction: state of the art. J Card Fail 2008; 14: 61-74.
144. McEntegart MB, Awede B, Petrie MC, et al. Increase in serum adiponectin concentration in patients with heart failure and cachexia: relationship with leptin, other cytokines, and B-type natriuretic peptide. Eur Heart J 2007; 28: 829-835.
145. Florea VG, Henein MY, Rauchhaus M, et al. The cardiac component of cardiac cachexia. Am Heart J 2002; 144: 45-50.
146. Florea VG, Moon J, Pennell DJ, Doehner W, Coats AJ, Anker SD,. Wasting of the left ventricle in patients with cardiac cachexia: a cardiovascular magnetic resonance study. Int J Cardiol 2004; 97: 15-20.
147. Schünemann M, Anker SD, Rauchhaus M,. Cancer fatigue syndrome reflects clinically non-overt heart failure: an approach towards onco-cardiology. Nat Clin Pract Oncol 2008; 5: 632-633.
148. von Haehling S,. Cardiac alterations in cancer cachexia. Abstracts of the 5th Cachexia Conference, Barcelona, Spain, December 5-8, 2009.